Clinical trial
Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has…
NCT00087503 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00087503 |
|---|---|
| Title | Intravenous Edotecarin in Patients With Advanced Gastric Cancer That Has Progressed or Recurred After Chemotherapy |
| Official title | A Phase II Efficacy And Safety Study Intravenous Edotecarin In Patients With Advanced Gastric Cancer That Has Progressed Or Recurred After Prior Fluropyrimidine-Based Chemotherapy |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stomach Neoplasms |
| Intervention type | Drug |
| Interventions | Edotecarin |
| Enrollment | 28 |
| Start date | Apr 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Jul 13, 2004 |
| Last update posted | Apr 1, 2008 |
| Countries | Belgium, France, Spain, Taiwan, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: